Amiodarone - a 'broad spectrum' antiarrhythmic drug

Area of Science:

• Pharmacology
• Cardiology

Background:

• Amiodarone, an iodinated benzofuran derivative, is a widely prescribed anti-arrhythmic medication.
• It exhibits Class I, II, III, and IV anti-arrhythmic actions, offering broad efficacy.
• Considered safe for patients with coronary artery disease and left ventricular systolic dysfunction due to minimal negative inotropic effects and low pro-arrhythmia risk.

Purpose of the Study:

• To review the pharmacokinetics, clinical indications, toxicity management, and drug interactions of amiodarone.
• To highlight amiodarone's unique multi-class anti-arrhythmic properties and safety profile in specific patient populations.

Main Methods:

• Literature review of amiodarone's properties and clinical use.
• Analysis of pharmacokinetic data, clinical trial outcomes, and post-marketing surveillance reports.

Main Results:

• Amiodarone is effective for ventricular and atrial arrhythmias but associated with potential long-term side effects affecting multiple organs.
• Optimal maintenance dose (200-300 mg/day) can minimize toxicity.
• Significant drug interactions exist, particularly with agents metabolized by Cytochrome P450, necessitating dose adjustments.

Conclusions:

• Close patient monitoring is essential during long-term amiodarone therapy.
• Amiodarone requires careful management due to its side effect profile and drug interactions.
• Contraindicated in pregnancy and breastfeeding (Category D).